GLP1R and Alzheimer disease: In addition, research results suggest that drugs such as lixisenatide and the GLP-1 analog CJC-1131 have the potential to protect against Aβ suppression in the LTP range, which may indicate the ability of these compounds to maintain or restore normal synaptic function, which is crucial in the context of improving cognitive function and delaying AD progression [177,178].